These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 15728776)
1. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. Bennett WM J Am Soc Nephrol; 2005 Apr; 16(4):838-9. PubMed ID: 15728776 [No Abstract] [Full Text] [Related]
2. Tolvaptan in autosomal dominant polycystic kidney disease. Jouret F; Krzesinski JM N Engl J Med; 2013 Mar; 368(13):1258-9. PubMed ID: 23534572 [No Abstract] [Full Text] [Related]
3. Tolvaptan in autosomal dominant polycystic kidney disease. Sexton DJ N Engl J Med; 2013 Mar; 368(13):1258. PubMed ID: 23534571 [No Abstract] [Full Text] [Related]
4. Tolvaptan in autosomal dominant polycystic kidney disease. Kher A N Engl J Med; 2013 Mar; 368(13):1257-8. PubMed ID: 23534570 [No Abstract] [Full Text] [Related]
5. Tolvaptan in autosomal dominant polycystic kidney disease. Spital A N Engl J Med; 2013 Mar; 368(13):1257. PubMed ID: 23534569 [No Abstract] [Full Text] [Related]
6. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back. Devuyst O; Wang X; Serra A Nephrol Dial Transplant; 2011 Aug; 26(8):2423-5. PubMed ID: 21803730 [No Abstract] [Full Text] [Related]
7. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease. Kawada T Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257 [No Abstract] [Full Text] [Related]
9. Aquaretic treatment in polycystic kidney disease. Wüthrich RP; Mei C N Engl J Med; 2012 Dec; 367(25):2440-2. PubMed ID: 23121376 [No Abstract] [Full Text] [Related]
10. In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease". Horie S; Muto S Clin Exp Nephrol; 2016 Feb; 20(1):149-50. PubMed ID: 26586005 [No Abstract] [Full Text] [Related]
11. [Cystic kidneys can now be treated]. Schumacher B MMW Fortschr Med; 2015 Sep; 157(15):26. PubMed ID: 26349712 [No Abstract] [Full Text] [Related]
12. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)]. Lacquaniti A G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083527 [No Abstract] [Full Text] [Related]